January 2005

Contents

Editorial

• Volume 6 Number 1 December 2004/January 2005

Treatment alerts

• Important new clinical data: potential early virologic failure associated with the combination antiretroviral regimen of tenofovir disoproxil fumarate, didanosine, and either efavirenz or nevirapine in HIV treatment-naive patients with high baseline viral loads

Conference reports

• 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (IWADRLH) 26-28 October 2004, Washington

• Nucleoside analogue-related mitochondrial toxicity and link to lipoatrophy: effect of non-thymidine analogues abacavir and tenofovir

• Nucleosides reduce PPAR-gamma: a role for rosiglitazone without thymidine analogues?

• Potential for uridine to treat mitochondrial toxicity: still only in vitro data

• 25% patients take Kaletra on an empty stomach: dietary advice often missed at ‘centre of excellence’

• rHGH reduces central fat accumulation in adolescent lipodystrophy

• Weight loss is associated with elevated PBMC proviral DNA levels

• Coronary artery bypass graft is safe in HIV-positive patients but shows higher risk of longer term events

• Endothelial dysfunction similar in ARV-experienced and -naive patients

• Pravastatin improves lipid profiles but not endothelial function

• Indinavir impairs endothelial function without insulin resistance

• Treatment interruptions improve lipids within four weeks: IL-2 has no metabolic effect

• Improvement of lipids following switch to tenofovir

• HCV coinfection linked to discontinuing ART due to toxicity

• Restorative treatments for HIV-associated lipoatrophy

• 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 30 October-2 November 2004, Washington

• Tipranavir in treatment experienced patients: results from RESIST-1

• Reverset: first data in patients with nucleoside resistance

• Poor response with tenofovir and ddI backbone causes early study termination

• Paradoxical CD4 response with tenofovir and ddI backbone

• Tenofovir/FTC backbone outperforms AZT/3TC (Combivir) with efavirenz in treatment naive patients; reduced toxicity drives ITT viral efficacy

• Limited stability of lopinavir/r (Kaletra) above 25°C

• Atorvastatin requires dose reduction with tipranavir/r

• Once-daily T-20 is less effective than twice daily: lower potency is related to C trough

• Further genetic link to efavirenz absorption

• Long-term response to FTC in children is similar to adults

• Side effects update: hypersensitivity, heart, bones

Antiretrovirals

• Roche discontinue plans for nelfinavir 625mg formulation

Treatment access

• Generic ARVs and WHO prequalification list

• Cotrimoxazole reduces mortality and morbidity in HIV-positive children: joint WHO/UNAIDS/UNICEF statement

• Equitable access for antiretroviral treatment for women

Guidelines

• US treatment guidelines updated (Jan 2005)

• Updated UK guidelines for HIV and hepatitis coinfection (2005)

Hepatitis coinfection

• Interferon plus 3TC for people with HIV/HBV coinfection

On the web

• 55th Annual Meeting of the American Society for the Study of Liver Diseases (55th AASLD), 29 October – 2 November, 2004, Boston MA

• Conference abstracts and reports

• Update your WHO/EDM bookshelf

• HIV InSite Knowledge Base

• Journal articles online at Medscape

• Facing up to it: Bio-Alcamid as a facial filler to treat lipoatrophy

PDFs

• Volume 6 Number 1 December 2004/January 2005 PDF